Key result
Serum aldolase A levels were elevated (>300 ng/ml) in 75% of patients with renal cell carcinoma compared to 6.3% of individuals with urogenital benign diseases.
Observational (n=122)
Absolute Event Rate: 75% vs 6.3%
Aldolase B changes into aldolases A and C during carcinogenesis in RCC, suggesting serum aldolase A could serve as a novel biomarker for the disease.
May support aldolase A as RCC biomarker; hypothesis-generating and requires prospective validation before clinical use.
To assess changes in aldolase isozyme patterns (A, B, and C) in renal cell carcinoma (RCC) tissues and to evaluate whether serum aldolase A might be a useful marker for RCC, quantitative analysis by enzyme immunoassay and immunohistochemical localization were performed. Concentrations of aldolase A in RCC (7300 +/- 6300 ng./mg. protein n = 26) were significantly higher than those of normal cortex (720 +/- 410 ng./mg. protein, n = 14, p less than 0.01); concentrations of aldolase C in RCC (48.0 +/- 8.0 ng./mg. protein) were also significantly higher than those of normal cortex (8.7 +/- 4.7 ng./mg. protein, p less than 0.01). On the other hand, concentrations of aldolase B in normal cortex were 18,100 +/- 10,100 ng./mg. protein (n = 14), whereas the values in RCC were only 130 +/- 270 ng./mg. protein, a significant lowering (p less than 0.01). Immunohistochemically, aldolases A and C were found localized in all RCC tissues (n = 10); aldolase B was faintly stained in only a few tumor cells of two cases (20%). Levels of serum aldolase A were elevated (greater than 300 ng./ml.) in 30 (75%) of 40 patients with RCC as compared to three (6.3%) of 48 individuals with urogenital benign diseases and in seven (21%) of 34 cases with non-RCC urogenital malignancies. Since it is generally accepted that RCC are derived from renal proximal tubules, these findings indicate that aldolase B, the predominant isozyme in the normal case, changes into aldolases A and C during carcinogenesis and that serum aldolase A could be a new useful biomarker for RCC.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (1991) conducted an observational in Renal cell carcinoma (n=122). Renal cell carcinoma vs. Urogenital benign diseases was evaluated on Elevated serum aldolase A (>300 ng/ml). Serum aldolase A levels were elevated (>300 ng/ml) in 75% of patients with renal cell carcinoma compared to 6.3% of individuals with urogenital benign diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: